citalopram and Lupus Erythematosus, Systemic
citalopram has been researched along with Lupus Erythematosus, Systemic in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
"We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Roh, EK | 1 |
Vleugels, RA | 1 |
Hoang, MP | 1 |
Puri, PK | 1 |
Lountzis, NI | 1 |
Tyler, W | 1 |
Ferringer, T | 1 |
Other Studies
2 other studies available for citalopram and Lupus Erythematosus, Systemic
Article | Year |
---|---|
Case records of the Massachusetts General Hospital. Case 39-2013. A 57-year-old woman with painful bullous skin lesions.
Topics: Biopsy; Citalopram; Diagnosis, Differential; Female; Glucocorticoids; Humans; Immunosuppressive Agen | 2013 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2008 |